Crizanlizumab — Discount Pricing

Other medications in Blood Disorders

• Darbepoetin
• Desmopressin IV
• Eltrombopag
• Emicizumab
• Epoetin Alfa
• Factor IX
• Factor VIII
• Filgrastim

About Crizanlizumab

Crizanlizumab is an innovative monoclonal antibody medication designed to reduce vaso-occlusive crises in patients with sickle cell disease. This groundbreaking treatment has transformed outcomes for many individuals managing this serious genetic condition. TheDrugClub members can access crizanlizumab with $0 co-pays and free home delivery, making this life-changing medication more affordable than ever.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Crizanlizumab is approved for (FDA label)

ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.

Source: Read the full FDA label on DailyMed. Label effective date: June 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Crizanlizumab (FDA label)

Injection: 100 mg/10 mL (10 mg/mL) as a clear to opalescent, colorless to slightly brownish-yellow solution in a single-dose vial. Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial.

Source: FDA prescribing information (DailyMed). Set ID: b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6. SPL document ID: 94577a82-7545-4421-ade9-108653361a16. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Crizanlizumab (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Infusion-related reactions [see Warnings and Precautions (5.1)] The most common adverse reactions (incidence ≥ 10%) were headache, arthralgia, nausea, back pain, fatigue, abdominal pain, pyrexia, diarrhea, vomiting, and oropharyngeal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6. SPL document ID: 94577a82-7545-4421-ade9-108653361a16. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Crizanlizumab (FDA label)

Infusion-Related Reactions: Monitor for and advise patients of signs and symptoms. Discontinue ADAKVEO infusion for severe reactions and manage medically. Temporarily interrupt or slow the rate of infusion for mild or moderate infusion-related reactions and initiate symptomatic treatment. Exercise caution with corticosteroids in patients with sickle cell disease unless clinically indicated (e.g., treatment of anaphylaxis). ( 5.1 ) Interference With Automated Platelet Counts (platelet clumping): Run test as soon as possible or use citrate tubes. ( 5.2 ) 5.1 Infusion-Related Reactions In the SUSTAIN clinical trial, infusion-related reactions (IRRs) (defined as occurring during/within 24 hours of infusion) were observed in 2 (3%) patients treated with ADAKVEO 5 mg/kg. In the STAND clinical trial, IRRs were observed in 6 (7%) patients treated with ADAKVEO 5 mg/kg. IRRs presented most frequently as pain, nausea, vomiting, fatigue, dizziness, pruritis, diarrhea, and pyrexia. Some IRRs have required hospitalizations.

Source: FDA prescribing information (DailyMed). Set ID: b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6. SPL document ID: 94577a82-7545-4421-ade9-108653361a16. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Crizanlizumab (FDA label)

7.1 Laboratory Test Interference Platelet Tests ADAKVEO interferes with automated platelet counts (platelet clumping) in particular when blood samples are collected in tubes containing EDTA, which may lead to unevaluable or falsely decreased platelet counts. Run blood samples within 4 hours of blood collection or collect blood samples in tubes containing citrate. When needed, estimate platelet count via peripheral blood smear.

Source: FDA prescribing information (DailyMed). Set ID: b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6. SPL document ID: 94577a82-7545-4421-ade9-108653361a16. Label effective date: June 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.